Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 20;86(8):4634-4642.
doi: 10.1097/MS9.0000000000002302. eCollection 2024 Aug.

Soluble platelet selectin and platelets in COVID-19: a multifaceted connection

Emmanuel Ifeanyi Obeagu  1 , Getrude Uzoma Obeagu  2 , Patrick Maduabuchi Aja  3   4 , G I A Okoroiwu  5 , N I Ubosi  5 , Theophilus Pius  1 , Muhammad Ashiru  5 , Kingsley Akaba  6 , Teddy Charles Adias  7
Affiliations
Review

Soluble platelet selectin and platelets in COVID-19: a multifaceted connection

Emmanuel Ifeanyi Obeagu et al. Ann Med Surg (Lond). .

Abstract

The COVID-19 pandemic has brought to light the intricate relationship between platelets, soluble platelet selectin (sP-selectin), and disease pathogenesis. Platelets, traditionally recognized for their role in hemostasis, have emerged as key contributors to the immunothrombotic complications observed in COVID-19 patients. Concurrently, elevated levels of sP-selectin, indicative of platelet activation and endothelial injury, have been consistently identified in COVID-19 patients and have shown associations with disease severity and adverse outcomes. This multifaceted connection underscores the pivotal role of platelets and sP-selectin in orchestrating thromboinflammation, vascular dysfunction, and disease progression in COVID-19. Platelet activation triggers the release of inflammatory mediators and promotes platelet-leukocyte interactions, amplifying the systemic inflammatory response and exacerbating endothelial injury. Additionally, platelet-derived factors contribute to microvascular thrombosis, further exacerbating tissue damage and organ dysfunction in severe COVID-19. Elevated sP-selectin levels serve as biomarkers for disease severity and prognostication, aiding in risk stratification and early identification of patients at higher risk of adverse outcomes. Therapeutic strategies targeting platelet dysfunction and sP-selectin-mediated pathways hold promise in mitigating thromboinflammation and improving outcomes in COVID-19 patients. Antiplatelet agents, platelet inhibitors, and anti-inflammatory therapies represent potential interventions to attenuate platelet activation, inhibit platelet-leukocyte interactions, and alleviate endothelial dysfunction. A comprehensive understanding of the multifaceted connection between platelets, sP-selectin, and COVID-19 pathogenesis offers opportunities for tailored therapeutic approaches aimed at mitigating thromboinflammation and improving patient outcomes in this complex and challenging clinical setting.

Keywords: COVID-19; platelet; soluble platelet selectin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Obeagu EI, Babar Q. Covid-19 and sickle cell anemia: susceptibility and severity. J Clin Lab Res 2021;3:2768–0487.
    1. Obeagu EI. COVID 19: factors associated with implementation and practice of Covid-19 prevention. Int J Adv Multidiscip Res 2022;9:37–42.
    1. Ogar CO, Okoroiwu HU, Obeagu EI, et al. . Assessment of blood supply and usage pre-and during COVID-19 pandemic: a lesson from non-voluntary donation. Transfus Clin Biole 2021;28:68–72. - PMC - PubMed
    1. Nnodim J, Njoku-Obi T, Ohalete C, et al. . Perspective of Covid 19 hesistancy. Madonna Univ J Med Health Sci 2022;2:235–238.
    1. Morotti A, Barale C, Melchionda E, et al. . Platelet redox imbalance in hypercholesterolemia: a big problem for a small cell. Int J Mol Sci 2022;23:11446. - PMC - PubMed

LinkOut - more resources